NUVB

Nuvation Bio Inc.

3.02 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nuvation Bio Inc. stock is down -11.44% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 June’s closed higher than May. 100% of analysts rate it a buy.

About Nuvation Bio Inc.

Nuvation Bio Inc. focuses on the development of therapeutic candidates for oncology. Lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. Company was formerly known as RePharmation Inc.

  • HC Wainwright & Co.
    Mon Jun 3, 06:35
    buy
    confirm
  • Wedbush
    Fri May 24, 09:50
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 22, 06:31
    buy
    confirm